Overall, these findings are consistent with those in our prior report (22) of exome sequencing of tumor tissue from this study, which did not show any evidence of amplification or mutations in EGFR, ERBB2, or ERBB3 that would result in high levels of membrane staining and/or constitutively-active receptor. The gene discussed is EGFR; the disease is neoplasm.